D. Ross Camidge, MD, PhD

Professor - Division of Medical Oncology
Director of Thoracic Oncology
University of Colorado

“Targeted Therapy for Lung Cancer”

LEARNING OBJECTIVES

• To present recent clinical trial evidence for targeted therapy in NSCLC
• To demonstrate the utility of targeted therapy in the treatment of CNS metastases
• To discuss best-practices for the integration of pathological and molecular information in the management of NSCLC patients with oncogenic drivers

WEDNESDAY APRIL 3, 2019

HÔPITAL CHARLES-LEMOYNE
12:00 to 13:00
Room HN-106

NOUVEAU CHUM
17:00 to 18:00
Room D.S4.5030
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514-813-4510

Refreshments will be served.
To organize a videconference:
vsfo@mcgill.ca

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Servier, Shire, Takeda, Teva Canada Innovation